Journal of
Marketing Development and Competitiveness

Scholar Gateway

Abstracts prior to volume 5(1) have been archived!

Issue 5(1), October 2010 -- Paper Abstracts
Girard  (p. 9-22)
Cooper (p. 23-32)
Kunz-Osborne (p. 33-41)
Coulmas-Law (p.42-46)
Stasio (p. 47-56)
Albert-Valette-Florence (p.57-63)
Zhang-Rauch (p. 64-70)
Alam-Yasin (p. 71-78)
Mattare-Monahan-Shah (p. 79-94)
Nonis-Hudson-Hunt (p. 95-106)


Hepatitis C Virus Direct Acting Antivirals and Disruptive Innovation

Author(s): S. Mantravadi, D. Snider

Citation: S. Mantravadi, D. Snider, "Hepatitis C Virus Direct Acting Antivirals and Disruptive Innovation," Journal of Strategic Innovation and Sustainability, Vol. 12, Iss. 2, pp. 68-74

Article Type: Research paper

Publisher: North American Business Press


In 2011, a new wave of direct acting antiviral treatments to combat the hepatitis C virus entered the market. In this paper we discuss how the entrance of these pharmaceutical products fit the definition of a disruptive innovation along with how they affected patients, providers and insurers.